Cargando...
Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
Drug design of protein kinase inhibitors is now greatly enabled by thousands of publicly available X-ray structures, extensive ligand binding data, and optimized scaffolds coming off patent. The extensive data begin to enable design against a spectrum of targets (polypharmacology); however, the data...
Guardado en:
| Publicado en: | J Cheminform |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5496928/ https://ncbi.nlm.nih.gov/pubmed/29086093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13321-017-0229-8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|